BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase

Rhea-AI Summary

BioLife Solutions (NASDAQ: BLFS) won the INTERPHEX 2026 Biotech Innovation Award for its CellSeal® CryoCase, a rigid cryogenic containment system for frozen biologics.

Launched in 2025, CryoCase was designed to address documented cryobag failures by reinforcing structural protection during freezing, liquid nitrogen storage, distribution, and visual inspection while remaining compatible with closed system CGT workflows.

AI-generated analysis. Not financial advice.

News Market Reaction – BLFS

+2.77%

1 alert

+2.77% News Effect

On the day this news was published, BLFS gained 2.77%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Award Recognizes Technologies That Address Important Industry Needs and Advance Prior Standards

BOTHELL, Wash., April 21, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced it has received the INTERPHEX 2026 Biotech Innovation Award for its CellSeal® CryoCase, a rigid cryogenic containment system purpose-built for frozen biologic materials.

CellSeal CryoCase was developed in response to documented container failures in CGT manufacturing, where flexible cryobags have historically been susceptible to stress fractures and seal fatigue from cycles of controlled rate freezing, liquid nitrogen storage, and distribution. CryoCase provides reinforced structural protection across the full frozen product journey while remaining compatible with closed system manufacturing workflows.

As CGT programs scale toward commercialization, regulators are paying closer attention to how frozen products are handled and inspected. CryoCase supports visual inspection for container integrity and potential particulates while giving manufacturers greater confidence in containment across product development.

"We're pleased to receive this recognition from INTERPHEX, one of the industry's leading forums for pharmaceutical and biotechnology innovation," said Roderick de Greef, CEO of BioLife Solutions. "This award is meaningful validation that CryoCase addresses a real need in the market. We specifically built it to address containment challenges the industry is currently facing."

Launched in 2025, CryoCase is available as part of BioLife's CellSeal® portfolio. For more information, visit https://www.biolifesolutions.com/handling/cellseal-cryocase/.

About BioLife Solutions
BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit www.biolifesolutions.com or follow BioLife on LinkedIn and X.

Media & Investor Relations

At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com

Investors
Alliance Advisors IR
Jody Cain
(310) 691-7100
jcain@allianceadvisors.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-wins-interphex-2026-biotech-innovation-award-for-cellseal-cryocase-302749192.html

SOURCE BioLife Solutions, Inc.

FAQ

What did BioLife Solutions (BLFS) win at INTERPHEX 2026?

BioLife Solutions won the INTERPHEX 2026 Biotech Innovation Award for CellSeal CryoCase. According to the company, the award recognizes CryoCase's design addressing container failures and improving containment for frozen biologic materials.

What is CellSeal CryoCase and when did BLFS launch it?

CellSeal CryoCase is a rigid cryogenic containment system for frozen biologics launched in 2025. According to the company, it reinforces structural protection and remains compatible with closed system manufacturing workflows.

How does CryoCase address cryobag failures cited by BLFS?

CryoCase provides reinforced structural protection to reduce stress fractures and seal fatigue in frozen product handling. According to the company, it supports visual inspection and containment during freezing, storage, and distribution.

Will CryoCase affect regulatory scrutiny for CGT frozen product handling?

CryoCase is positioned to help manufacturers meet increasing regulator attention on frozen handling and inspection. According to the company, it supports visual integrity checks and gives greater confidence in containment.

Where can investors find more information about BLFS CellSeal CryoCase?

More information about CellSeal CryoCase is available on BioLife Solutions' product pages. According to the company, CryoCase is part of the CellSeal portfolio and was launched in 2025.